Kindbody hemorrhaging cash from clinic model
Kindbody
The key point is that Kindbody’s cash strain exposed the downside of trying to run a capital intensive clinic network like a software style growth company. The business had already expanded from one low cost Manhattan egg freezing clinic into 27 owned clinics and labs, plus 400 plus partner locations serving 135 employers by June 2025. That footprint can drive more revenue per patient than a benefits only model, but it also creates fixed costs in labs, doctors, and local operations that become painful when growth slows or fundraising tightens.
-
Kindbody makes money in three concrete ways, cash pay fertility services like egg freezing and IVF, employer fertility benefits contracts, and visits that flow through its owned clinics. That is different from Progyny and Maven, which mostly route members into outside provider networks instead of owning the care sites themselves.
-
That model looked powerful while growth was fast. Revenue rose from about $50M in 2021 to $120M in 2022 and $180M in 2023, and the company was valued at $1.8B in 2023. But the same model also required more operating cash than an asset light peer like Maven, which scaled through a provider network across 175 countries rather than clinic ownership.
-
The September 2025 reporting matters because it linked financial pressure to behavior inside the care workflow, including alleged retrieval quotas and pressure to sell higher cost IVF add ons. In fertility care, where patients are buying emotionally loaded and medically complex treatment, that kind of pressure can damage employer trust as much as patient trust.
Going forward, the winners in fertility benefits will be the companies that can combine broad access with tighter cost control. Kindbody’s path is to make its hybrid network work with much more discipline, so clinic ownership becomes a margin advantage instead of a cash drain, while preserving enough trust to keep winning employer contracts.